Should you build or buy Statistical Analysis Software?

Statistical analysis software runs hypothesis tests, regression, survival analysis and design-of-experiments work through a licensed interface. Researchers, quality engineers and regulated-industry statisticians use these tools, or the open-source R and Python ecosystem that does the same math, to turn raw data into a defensible analysis.

Open-source statistics is a documented production path, including regulated submissions; license commercial tools for non-programmers and validated environments only.

Build it, buy it, or bridge?

⚒ Build it
✓ Buy it
➔ Bridge
Cost shape
R and Python are free; a team pays instead in validation, environment management and training for non-programmers.
SPSS, JMP and Minitab license per seat, from roughly a thousand to several thousand dollars a year.
Run routine analysis in R; keep a GUI license for the handful of staff who need one.
Time to value
R has no learning curve for a statistician who already scripts; it's a real curve for one who doesn't.
SPSS and JMP hand a non-programmer a working analysis in minutes through point-and-click menus.
Script the reusable analyses in R; use a GUI tool for one-off exploratory work.
Differentiation captured
The methods are identical wherever you run them; nothing about R makes a regression more correct.
No lab or sponsor wins on which stats package it licenses; the differentiation is in the data and the analysis.
Own the analysis and the validated environment; the package is a solved commodity either way.
AI feasibility today
AI coding assistants make writing and validating R analysis scripts far faster than it was even a year ago.
Vendors are adding AI-assisted analysis suggestions inside SPSS and JMP's existing point-and-click workflow.
Let AI draft the R script; keep a licensed GUI tool only for staff who won't touch code.
Who it fits
A statistics-literate team that can own a validated R or Python environment without a vendor's help.
Non-programmer analysts, or a regulated program where a GUI and vendor support are worth the license.
A team with both populations: script-comfortable staff on R, everyone else on a licensed GUI tool.

When building makes sense

Building on R or Python instead of licensing SPSS, SAS or JMP is a mainstream choice for any team with statistics-literate staff, not a fringe one. The math is identical either way: regression, ANOVA, survival analysis and design-of-experiments are peer-reviewed methods, not vendor features, and the FDA's own 2015 Statistical Software Clarifying Statement says the agency does not require the use of any specific software for statistical analyses, only that whatever software is used be documented, including version and build. What building actually costs is the validation and environment-management work a vendor otherwise bundles: pinning package versions, documenting the computing environment and training people who don't already script. Posit's RStudio and Python's data-science stack cover that gap for teams that invest in it. Building is the right call for a team that already has the statistical and scripting skill in-house and doesn't need a point-and-click interface for occasional users.

When buying makes sense

Buying earns its keep for two groups: analysts who don't script and never will, and regulated programs that need a validated, supported environment with a vendor accountable for it. IBM's SPSS, SAS and JMP all sell a point-and-click interface that turns a working analysis into a few clicks rather than a script, which matters for staff whose job is the analysis, not the programming. The FDA's own Statistical Software Clarifying Statement makes clear it does not require any specific package. Buyers are really paying for the GUI and the support contract behind it. JMP Pro and SAS/STAT also bundle quality-engineering and design-of-experiments workflows that a niche of buyers use daily. Buying wins when the population using the tool includes people who need a menu instead of a script editor.

The desk read

Build-versus-buy analysis for Statistical Analysis Software is being written. In the meantime, the framework that drives every B4 call is on the B4 Index page.

Representative vendors JMPSAS/STAT + 5 more, listed in the full index

Frequently asked

What is statistical analysis software?

It exists because the same methods run through two different interfaces: a licensed point-and-click product built for a non-programmer, or a script in R or Python that a statistician comfortable with code can run for free. Neither interface changes the underlying math.

Does the FDA actually require SAS or SPSS for regulatory submissions?

No. The FDA's 2015 Statistical Software Clarifying Statement says it does not require the use of any specific software for statistical analyses, only that whatever software is used gets documented, including version and build identification. That leaves the door open to R-based submissions as long as the environment is validated and traceable.

Why would anyone pay $8,000 a year for JMP when R is free?

Mainly for the interface. JMP and SPSS turn common analyses into a few clicks, which matters for staff who aren't programmers, and JMP Pro bundles design-of-experiments and quality-engineering workflows a niche of buyers use constantly. The license is buying a menu and a support line, not a mathematical capability R lacks.

What does it actually cost to run R instead of licensing a vendor tool?

The license fee drops to zero, but a regulated or research team still has to fund validation, environment management and training for anyone who doesn't already script. That cost is real but shrinking as open-source governance frameworks for R in regulated settings keep maturing.

What are the main statistical analysis software vendors?

Representative vendors include JMP, SAS/STAT. B4 Pro includes the category score and the full vendor list.

The B4 Index scores every software category on two axes, strategic differentiation and AI feasibility, to classify it Build, Buy, Bridge, or Beware. See the full methodology.